The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury

Trial Profile

The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Osteoporosis; Spinal cord injuries
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top